GIMAP6 Inhibitors
GIMAP6 inhibitors encompass a class of chemical compounds specifically designed to target and inhibit the activity of the GTPase of the immunity-associated protein 6 (GIMAP6). GIMAP6 is involved in the regulation of the immune system, particularly in the survival and maintenance of T lymphocytes. The inhibitors in this category are characterized by their selective affinity to bind to the active sites of GIMAP6, thereby blocking its GTPase activity. This inhibition results in the disruption of GIMAP6's role in maintaining T-cell counts, as it can no longer hydrolyze GTP to GDP, a critical step for its function. The precise molecular interaction typically involves the occupation of the GTP-binding pocket, preventing the access of GTP to the active site of GIMAP6, which is crucial for its normal regulatory role in the immune response. The design of these inhibitors is based on the structure-activity relationship (SAR) studies, where the chemical structure is optimized to increase binding affinity and selectivity to GIMAP6 while minimizing off-target effects.
The specificity of GIMAP6 inhibitors is a key aspect of their biochemical profile. These compounds not only bind to the GTPase domain but are also tailored to interact with distinct regions that are unique to GIMAP6, ensuring that they do not inadvertently inhibit other GTPases within the GIMAP family or unrelated proteins. This specificity is achieved through the careful design of the inhibitor's chemical structure, which takes into account the three-dimensional conformation of the GIMAP6 active site. The development of these inhibitors involves computational modeling and empirical testing to confirm that the binding does not alter the conformation of the protein in a way that would activate it, but rather keeps it in an inactive state. The compounds usually have a high binding affinity, which is necessary to outcompete endogenous GTP molecules effectively and to ensure a sustained inhibitory action on GIMAP6 activity, thus influencing the immunoregulatory processes in which GIMAP6 is a key player.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
Sirolimus, also known as rapamycin, is an mTOR inhibitor that can lead to the functional inhibition of GIMAP6. mTOR signaling is crucial for lymphocyte development and function, and GIMAP6 is implicated in the survival and development of lymphocytes. By inhibiting mTOR, sirolimus negatively impacts lymphocyte function, thereby reducing GIMAP6 activity which is essential for lymphocyte maintenance. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
LY294002 is a PI3K inhibitor, which indirectly inhibits GIMAP6 by disrupting PI3K/AKT/mTOR signaling, a pathway essential for lymphocyte differentiation and survival where GIMAP6 plays a role. Inhibition of this pathway will decrease cell survival signaling, potentially diminishing the functional activity of GIMAP6. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $67.00 $223.00 $425.00 | 97 | |
Wortmannin is another PI3K inhibitor that, like LY294002, impedes the PI3K/AKT/mTOR pathway. Through this inhibition, the survival and proliferation signals in lymphocytes are reduced, which indirectly decreases the functional activity of GIMAP6 due to its role in these processes. | ||||||
Lenalidomide | 191732-72-6 | sc-218656 sc-218656A sc-218656B | 10 mg 100 mg 1 g | $50.00 $374.00 $2071.00 | 18 | |
Lenalidomide exerts its effects in part by affecting the ubiquitination and degradation of proteins involved in lymphocyte function. Given the role of GIMAP6 in lymphocyte survival, lenalidomide could indirectly decrease GIMAP6 activity by modulating the environment and promoting the degradation of proteins that support GIMAP6 function. | ||||||
Bortezomib | 179324-69-7 | sc-217785 sc-217785A | 2.5 mg 25 mg | $135.00 $1085.00 | 115 | |
Bortezomib is a proteasome inhibitor that can lead to the accumulation of ubiquitinated proteins, indirectly influencing GIMAP6 by causing stress in lymphocytes, which may impair the cellular processes where GIMAP6 is involved, leading to its functional inhibition. | ||||||
PP242 | 1092351-67-1 | sc-301606A sc-301606 | 1 mg 5 mg | $57.00 $172.00 | 8 | |
PP242 is an ATP-competitive inhibitor of mTOR that, unlike rapamycin, inhibits both mTORC1 and mTORC2 complexes. Inhibition of these complexes can suppress lymphocyte development and function, thereby indirectly reducing GIMAP6 activity which is associated with lymphocyte survival. | ||||||
Spautin-1 | 1262888-28-7 | sc-507306 | 10 mg | $168.00 | ||
Spautin-1 is a specific inhibitor of autophagy that promotes the degradation of PI3K class III, which is involved in the early initiation of autophagy. GIMAP6 has been associated with autophagy in immune cells, and inhibiting this process could thus decrease GIMAP6's functional activity by interfering with its role in autophagic processes. | ||||||
Sunitinib, Free Base | 557795-19-4 | sc-396319 sc-396319A | 500 mg 5 g | $153.00 $938.00 | 5 | |
Sunitinib is a receptor tyrosine kinase inhibitor that could indirectly affect GIMAP6 by inhibiting signaling pathways important for lymphocyte survival and activation, thereby potentially reducing GIMAP6 functional activity. | ||||||
Sorafenib | 284461-73-0 | sc-220125 sc-220125A sc-220125B | 5 mg 50 mg 500 mg | $57.00 $100.00 $250.00 | 129 | |
Sorafenib, a kinase inhibitor, may indirectly decrease GIMAP6 activity by inhibiting RAF/MEK/ERK signaling, which is involved in lymphocyte proliferation and survival. As GIMAP6 is associated with these cells, sorafenib could reduce GIMAP6's functionality by affecting the signaling environment in which it operates. | ||||||
Imatinib | 152459-95-5 | sc-267106 sc-267106A sc-267106B | 10 mg 100 mg 1 g | $26.00 $119.00 $213.00 | 27 | |
Imatinib is a tyrosine kinase inhibitor that can impede BCR-ABL and other kinases. Though not directly affecting GIMAP6, it could indirectly inhibit its function by modulating the signaling pathways involved in lymphocyte development and survival, where GIMAP6 is essential. | ||||||